IL133618A - Crystalline dibenzothiazepine derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof as antipsychotic agents - Google Patents

Crystalline dibenzothiazepine derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof as antipsychotic agents

Info

Publication number: IL133618A
Authority: IL; Israel
Prior art keywords: dibenzo; thiazepine; hydroxyethoxy; piperazinyl; ethyl
Prior art date: 1997-08-01

Application number

IL13361898A

Other languages

English (en)

Other versions

IL133618A0 (en

Original Assignee

Zeneca Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-01

Filing date

1998-07-28

Publication date

2004-02-08

1998-07-28 Application filed by Zeneca Ltd filed Critical Zeneca Ltd

2001-04-30 Publication of IL133618A0 publication Critical patent/IL133618A0/xx

2004-02-08 Publication of IL133618A publication Critical patent/IL133618A/en

Links

238000000034 method Methods 0.000 title claims description 35
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
238000002360 preparation method Methods 0.000 title description 10
239000000164 antipsychotic agent Substances 0.000 title description 3
150000008509 dibenzothiazepines Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 21
NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 claims description 72
150000003839 salts Chemical class 0.000 claims description 36
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 25
239000003849 aromatic solvent Substances 0.000 claims description 24
239000002904 solvent Substances 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 13
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 12
230000003247 decreasing effect Effects 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
238000002425 crystallisation Methods 0.000 claims description 8
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 7
239000008346 aqueous phase Substances 0.000 claims description 7
150000001450 anions Chemical class 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
239000012071 phase Substances 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000001530 fumaric acid Substances 0.000 claims description 5
208000028017 Psychotic disease Diseases 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 3
FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 3
OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 3
239000012074 organic phase Substances 0.000 claims description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
238000001035 drying Methods 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
-1 hydroxyethoxy Chemical group 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
229940043265 methyl isobutyl ketone Drugs 0.000 claims description 2
125000003944 tolyl group Chemical group 0.000 claims description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 description 16
239000007787 solid Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 8
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000002585 base Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000012258 stirred mixture Substances 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
239000002178 crystalline material Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
235000015096 spirit Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
QPPOMEOQNLTFRU-UHFFFAOYSA-N 1,4-thiazepine Chemical compound S1C=CC=NC=C1 QPPOMEOQNLTFRU-UHFFFAOYSA-N 0.000 description 1
BOCDFJFSOVIHBY-UHFFFAOYSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-7-ylpiperazin-1-yl)ethoxy]ethanol Chemical compound C1CN(CCOCCO)CCN1C1=CC=CC2=C1C=NC1=CC=CC=C1S2 BOCDFJFSOVIHBY-UHFFFAOYSA-N 0.000 description 1
RSEHHYMPNZWTGQ-UHFFFAOYSA-N 3-piperazin-4-ium-1-ylpropanoate Chemical compound OC(=O)CCN1CCNCC1 RSEHHYMPNZWTGQ-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
230000001090 anti-dopaminergic effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
239000003874 central nervous system depressant Substances 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000005007 materials handling Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000004912 thiazepines Chemical class 0.000 description 1
229940125725 tranquilizer Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychiatry (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Glass Compositions (AREA)
Iron Core Of Rotating Electric Machines (AREA)
Liquid Crystal Substances (AREA)

IL13361898A 1997-08-01 1998-07-28 Crystalline dibenzothiazepine derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof as antipsychotic agents IL133618A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9716161.6A GB9716161D0 (en)	1997-08-01	1997-08-01	Process
PCT/GB1998/002260 WO1999006381A1 (en)	1997-08-01	1998-07-28	A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent

Publications (2)

Publication Number	Publication Date
IL133618A0 IL133618A0 (en)	2001-04-30
IL133618A true IL133618A (en)	2004-02-08

Family

ID=10816746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13361898A IL133618A (en)	1997-08-01	1998-07-28	Crystalline dibenzothiazepine derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof as antipsychotic agents

Country Status (31)

Country	Link
US (2)	US6372734B1 (de)
EP (2)	EP1000043B1 (de)
JP (2)	JP2001512109A (de)
KR (1)	KR20010022241A (de)
CN (1)	CN1125058C (de)
AT (2)	ATE444959T1 (de)
AU (1)	AU739255B2 (de)
BG (1)	BG64796B1 (de)
BR (1)	BR9811061A (de)
CA (1)	CA2295792C (de)
CY (2)	CY2200162T2 (de)
CZ (1)	CZ299225B6 (de)
DE (4)	DE69841216D1 (de)
EE (1)	EE04550B1 (de)
ES (2)	ES2296575T3 (de)
GB (2)	GB9716161D0 (de)
HU (1)	HU228620B1 (de)
ID (1)	ID24219A (de)
IL (1)	IL133618A (de)
MY (1)	MY120999A (de)
NO (1)	NO20000484L (de)
NZ (1)	NZ501914A (de)
PL (1)	PL338384A1 (de)
PT (2)	PT1589008E (de)
RU (1)	RU2224754C2 (de)
SI (2)	SI1589008T1 (de)
SK (1)	SK287145B6 (de)
TR (1)	TR200000848T2 (de)
TW (1)	TW533207B (de)
WO (1)	WO1999006381A1 (de)
ZA (1)	ZA986904B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL164155A0 (en) *	2002-03-20	2005-12-18	Teva Pharma	Crystalline forms of quetiapine hemifumarate
CN1777594A (zh) *	2003-02-22	2006-05-24	特瓦制药工业有限公司	喹迪平及其可药用盐的合成
US7238686B2 (en) *	2003-03-03	2007-07-03	Hetero Drugs Limited	Polymorphs of quetiapine fumarate
WO2004089957A1 (en) *	2003-04-07	2004-10-21	Hetero Drugs Limited	A novel crystalline form of dorzolamide hydrochloride
ES2223294B2 (es)	2003-08-08	2005-10-01	Vita Cientifica, S.L.	Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20060081361A1 (en) *	2004-09-13	2006-04-20	Gabbey Lawrence W	Oil cooler with integral filter
WO2006035293A1 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Polymorphic forms of quetiapine hemifumarate
GB0425729D0 (en) *	2004-11-23	2004-12-22	Pliva Res & Dev Ltd	Heterocyclic compounds
WO2006056772A2 (en) *	2004-11-23	2006-06-01	Pliva Hrvatska D.O.O.	Salts of quetiapine
ES2234447B1 (es) *	2005-03-07	2006-03-01	Union Quimico-Farmaceutica S.A.	Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
US7687622B2 (en)	2005-04-14	2010-03-30	Teva Pharmaceutical Industries, Ltd	Process for preparing quetiapine fumarate
US20070072840A1 (en) *	2005-05-30	2007-03-29	Pandya Bhargav	Polymorphic forms of quetiapine
WO2007036599A1 (en)	2005-09-30	2007-04-05	Fermion Oy	New crystallization process of quetiapine hemifumarate
WO2007048870A1 (en) *	2005-10-28	2007-05-03	Fermion Oy	Quetiapine hemifumarate purification by crystallization
US8389510B2 (en) *	2005-11-18	2013-03-05	Astrazeneca Ab	Crystalline forms
JP2009516705A (ja) *	2005-11-18	2009-04-23	アストラゼネカ・アクチエボラーグ	塩の形態
WO2007062339A2 (en) *	2005-11-18	2007-05-31	Astrazeneca Ab	Liquid formulations
WO2007062338A2 (en) *	2005-11-18	2007-05-31	Astrazeneca Ab	Solid formulations
WO2007062337A2 (en) *	2005-11-18	2007-05-31	Astrazeneca Ab	Crystalline forms
CZ300451B6 (cs) *	2006-07-03	2009-05-20	Farmak, A. S.	Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008066620A2 (en) *	2006-10-20	2008-06-05	Concert Pharmaceuticals Inc.	Dibenzothiazepine derivatives
ATE480227T1 (de)	2007-02-14	2010-09-15	Lesvi Laboratorios Sl	Pharmazeutische zusammensetzungen mit quetiapinfumarat
EP2144892A2 (de) *	2007-03-29	2010-01-20	Teva Pharmaceutical Industries Ltd.	Verbessertes verfahren zur herstellung von quetiapinfumaraten
WO2009004480A2 (en) *	2007-05-07	2009-01-08	Actavis Group Ptc Ehf	Quetiapine salts and their polymorphs
US20090082334A1 (en) *	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched quetiapine
KR101598558B1 (ko) *	2007-12-05	2016-02-29	얀센 파마슈티카 엔.브이.	디벤조아제핀 및 디벤조옥사제핀 ｔｒｐａ1 효능제
DE202009018024U1 (de)	2008-08-01	2010-12-09	Krka Tovarna Zdravil, D.D., Novo Mesto	Quetiapin-Zusammensetzung
US20100069356A1 (en) *	2008-09-17	2010-03-18	Auspex Pharmaceuticals, Inc.	Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
WO2010100623A1 (en)	2009-03-04	2010-09-10	Ranbaxy Laboratories Limited	Process for the preparation of quetiapine fumarate
EP3789500A1 (de)	2011-08-12	2021-03-10	QIAGEN GmbH	Verfahren zur isolierung von nukleinsäuren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787249A (fr)	1971-08-05	1973-02-05	Squibb & Sons Inc	Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
GB8607684D0 (en) *	1986-03-27	1986-04-30	Ici America Inc	Thiazepine compounds
GB8705574D0 (en) *	1987-03-10	1987-04-15	Ici Plc	Preparation of thiazepine compound

1997
- 1997-08-01 GB GBGB9716161.6A patent/GB9716161D0/en active Pending
1998
- 1998-07-10 GB GBGB9814882.8A patent/GB9814882D0/en active Pending
- 1998-07-28 SK SK130-2000A patent/SK287145B6/sk not_active IP Right Cessation
- 1998-07-28 CN CN98807572A patent/CN1125058C/zh not_active Expired - Fee Related
- 1998-07-28 IL IL13361898A patent/IL133618A/en not_active IP Right Cessation
- 1998-07-28 ES ES98936529T patent/ES2296575T3/es not_active Expired - Lifetime
- 1998-07-28 WO PCT/GB1998/002260 patent/WO1999006381A1/en not_active Ceased
- 1998-07-28 EP EP98936529A patent/EP1000043B1/de not_active Expired - Lifetime
- 1998-07-28 DE DE69841216T patent/DE69841216D1/de not_active Expired - Lifetime
- 1998-07-28 EP EP05011169A patent/EP1589008B1/de not_active Expired - Lifetime
- 1998-07-28 TR TR2000/00848T patent/TR200000848T2/xx unknown
- 1998-07-28 HU HU0002663A patent/HU228620B1/hu not_active IP Right Cessation
- 1998-07-28 CA CA002295792A patent/CA2295792C/en not_active Expired - Fee Related
- 1998-07-28 JP JP2000505140A patent/JP2001512109A/ja active Pending
- 1998-07-28 US US09/463,452 patent/US6372734B1/en not_active Expired - Lifetime
- 1998-07-28 NZ NZ501914A patent/NZ501914A/en not_active IP Right Cessation
- 1998-07-28 DE DE05011169T patent/DE05011169T1/de active Pending
- 1998-07-28 SI SI9830929T patent/SI1589008T1/sl unknown
- 1998-07-28 PT PT05011169T patent/PT1589008E/pt unknown
- 1998-07-28 BR BR9811061-6A patent/BR9811061A/pt not_active Application Discontinuation
- 1998-07-28 PL PL98338384A patent/PL338384A1/xx not_active Application Discontinuation
- 1998-07-28 DE DE98936529T patent/DE98936529T1/de active Pending
- 1998-07-28 TW TW087112313A patent/TW533207B/zh not_active IP Right Cessation
- 1998-07-28 ES ES05011169T patent/ES2296568T3/es not_active Expired - Lifetime
- 1998-07-28 ID IDW20000029A patent/ID24219A/id unknown
- 1998-07-28 RU RU2000105271/04A patent/RU2224754C2/ru not_active IP Right Cessation
- 1998-07-28 EE EEP200000062A patent/EE04550B1/xx not_active IP Right Cessation
- 1998-07-28 AT AT98936529T patent/ATE444959T1/de active
- 1998-07-28 CZ CZ20000341A patent/CZ299225B6/cs not_active IP Right Cessation
- 1998-07-28 AT AT05011169T patent/ATE496037T1/de active
- 1998-07-28 DE DE69842104T patent/DE69842104D1/de not_active Expired - Lifetime
- 1998-07-28 SI SI9830923T patent/SI1000043T1/sl unknown
- 1998-07-28 PT PT98936529T patent/PT1000043E/pt unknown
- 1998-07-28 AU AU85498/98A patent/AU739255B2/en not_active Ceased
- 1998-07-28 KR KR1020007000814A patent/KR20010022241A/ko not_active Ceased
- 1998-07-29 MY MYPI98003471A patent/MY120999A/en unknown
- 1998-07-31 ZA ZA986904A patent/ZA986904B/xx unknown
2000
- 2000-01-31 NO NO20000484A patent/NO20000484L/no unknown
- 2000-02-22 BG BG104176A patent/BG64796B1/bg unknown
2002
- 2002-03-21 US US10/101,948 patent/US20020147186A1/en not_active Abandoned
2008
- 2008-03-04 CY CY20082200005T patent/CY2200162T2/el unknown
- 2008-03-04 CY CY20082200004T patent/CY2200161T2/el unknown
- 2008-12-09 JP JP2008313248A patent/JP2009102345A/ja active Pending

Also Published As

Publication number	Publication date
CN1265101A (zh)	2000-08-30
PT1589008E (pt)	2011-03-23
KR20010022241A (ko)	2001-03-15
HU228620B1 (en)	2013-04-29
PL338384A1 (en)	2000-10-23
DE05011169T1 (de)	2008-11-06
PT1000043E (pt)	2009-11-30
EE200000062A (et)	2000-10-16
RU2224754C2 (ru)	2004-02-27
NO20000484L (no)	2000-03-16
CY2200162T2 (el)	2010-07-28
BG104176A (en)	2000-08-31
HK1029992A1 (en)	2001-04-20
BR9811061A (pt)	2000-09-19
ATE444959T1 (de)	2009-10-15
IL133618A0 (en)	2001-04-30
HK1081962A1 (en)	2006-05-26
SI1000043T1 (sl)	2010-01-29
BG64796B1 (bg)	2006-04-28
CA2295792A1 (en)	1999-02-11
NZ501914A (en)	2001-09-28
DE69841216D1 (de)	2009-11-19
DE98936529T1 (de)	2008-11-20
SI1589008T1 (sl)	2011-04-29
CZ2000341A3 (cs)	2000-05-17
ATE496037T1 (de)	2011-02-15
MY120999A (en)	2005-12-30
JP2001512109A (ja)	2001-08-21
HUP0002663A2 (hu)	2001-09-28
ES2296568T3 (es)	2011-05-06
TR200000848T2 (tr)	2000-08-21
AU739255B2 (en)	2001-10-04
WO1999006381A1 (en)	1999-02-11
GB9716161D0 (en)	1997-10-08
EP1589008B1 (de)	2011-01-19
HUP0002663A3 (en)	2001-10-29
EE04550B1 (et)	2005-10-17
SK1302000A3 (en)	2000-06-12
DE69842104D1 (de)	2011-03-03
NO20000484D0 (no)	2000-01-31
CY2200161T2 (el)	2010-07-28
ES2296568T1 (es)	2008-05-01
ID24219A (id)	2000-07-13
JP2009102345A (ja)	2009-05-14
ES2296575T3 (es)	2010-02-05
TW533207B (en)	2003-05-21
CZ299225B6 (cs)	2008-05-21
GB9814882D0 (en)	1998-09-09
EP1000043A1 (de)	2000-05-17
AU8549898A (en)	1999-02-22
EP1589008A1 (de)	2005-10-26
US6372734B1 (en)	2002-04-16
ES2296575T1 (es)	2008-05-01
CA2295792C (en)	2007-04-17
CN1125058C (zh)	2003-10-22
US20020147186A1 (en)	2002-10-10
EP1000043B1 (de)	2009-10-07
ZA986904B (en)	1999-02-01
SK287145B6 (sk)	2010-01-07

Legal Events

Date	Code	Title
2004-06-20	FF	Patent granted
2004-07-25	KB	Patent renewed
2008-11-27	KB	Patent renewed
2012-07-31	KB	Patent renewed
2017-02-28	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CA2295792C (en)	2007-04-17	A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
IL104740A (en)	1996-09-12	Hypolipidaemic benzothiazepine compounds their preparation and pharmaceutical compositions containing them
RU2000105271A (ru)	2002-03-20	Кристаллическое производное дибензотиазепина и его использование в качестве средства для борьбы с психозами
EP0240228A1 (de)	1987-10-07	Thiazepinverbindungen
IE59056B1 (en)	1993-12-15	4-benzyl-1-(2h)-phthalazinone derivatives
WO2004078735A1 (en)	2004-09-16	Novel polymorphs of quetiapine fumarate
EP0357126B1 (de)	1994-04-27	Tetracyclische Antidepressiva
CA2164296C (en)	2007-01-23	Heterocyclic chemistry
HK1081962B (en)	2011-07-15	A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
MXPA00000511A (en)	2001-05-07	A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
JP3345814B2 (ja)	2002-11-18	２６―（ジアルキルアミノアルキルスルホニル）プリスチナマイシンｉｉｂから誘導される新規な塩類
JPH0374661B2 (de)	1991-11-27
HK1029992B (en)	2004-07-09	A crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
WO1999061441A1 (en)	1999-12-02	Polymorphs of crystalline (7s,9as)-7-[ 3-cyanophenoxy] methyl-2-(5- fluoropyrimidin-2- yl)-2,3,4,6,7,8,9a -octahydro-1h-pyrido[1,2-a] pyrazine- monohydrochloride and their pharmaceutical compositions
WO2003042161A1 (en)	2003-05-22	Venlafaxine hydrochloride polymorphs
HUT70181A (en)	1995-09-28	Novel arylpiperidine, process for producing thereof and pharmaceutical compositions comprising these compound